期刊
ALZHEIMERS & DEMENTIA
卷 6, 期 5, 页码 420-424出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2010.04.006
关键词
Alzheimer disease subgroups; Cerebrospinal fluid; CSF biomarkers; A beta(1-42); Tau; Ubiquitin; Alzheimer disease therapeutics; Neurofibrillary degeneration; beta-amyloid
资金
- New York State Office of Mental Retardation and Developmental Disabilities
- NIH [AG019158, AG028538]
- Alzheimer's Association (Chicago, IL) [IIRG-00-2002, HRG-05-13095]
Alzheimer's disease (AD) is multifactorial and apparently involves several different etiopathogenic mechanisms. There are at least five subgroups of AD based on cerebrospinal fluid levels of A beta(1-42), a marker of beta-amyloid (A beta) plaques, and tau and ubiquitin, two markers of neurofibrillary tangles. These different AD subgroups may respond differently to a given disease-modifying drug, and hence, different therapeutic drugs for different disease subgroups might be required. Stratification of AD patients by disease subgroups in clinical trials is critical to the successful development of potent disease-modifying drugs. Levels of disease markers in the cerebrospinal fluid are promising, both in identifying various subgroups of AD and in monitoring the response to therapeutic drugs. (c) 2010 The Alzheimer's Association. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据